These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31474863)

  • 21. The similarity of pharmacokinetics, pharmacodynamics, safety, and immunogenicity between recombinant fully human anti-RANKL monoclonal antibody injection (MW032) and denosumab (Xgeva®) in healthy Chinese subjects: A single-center, randomized, double-blind, single-dose, parallel-controlled clinical study.
    Hou J; Hu Z; Xu W; Di Y; Song C; Wu F; Liu J; Guo Y
    Int Immunopharmacol; 2022 Jun; 107():108666. PubMed ID: 35286913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.
    Cao G; Yu J; Wu J; Wang J; Xue Y; Yang X; Zhang J
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):317-325. PubMed ID: 32463599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
    Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects.
    Qian H; Cheng J; Gui Y; Wang W; Liang L; Zhu H; Wu Q; Ou M; Chen Q; Yu C; Jia J
    Clin Transl Sci; 2023 Sep; 16(9):1704-1712. PubMed ID: 37403258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects.
    Hettema W; Wynne C; Lang B; Altendorfer M; Czeloth N; Lohmann R; Athalye S; Schliephake D
    Expert Opin Investig Drugs; 2017 Aug; 26(8):889-896. PubMed ID: 28651442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 1 study comparing the proposed biosimilar BS-503a with bevacizumab in healthy male volunteers.
    Tajima N; Martinez A; Kobayashi F; He L; Dewland P
    Pharmacol Res Perspect; 2017 Apr; 5(2):e00286. PubMed ID: 28357118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects.
    Bush J; Kawakami K; Muniz R
    BMC Pharmacol Toxicol; 2019 Dec; 20(1):87. PubMed ID: 31888742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind, single-dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab.
    Schwabe C; Cole A; Espigares-Correa A; Beydon ME; Florez-Igual A; Queiruga-Parada J
    Pharmacol Res Perspect; 2023 Apr; 11(2):e01070. PubMed ID: 36914963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects.
    Zhang H; Chen H; Li X; Wu M; Zhu X; Li C; Liu J; Wei H; Hu Y; Wang J; Yang Y; Zhu X; Ding Y
    Front Pharmacol; 2021; 12():646171. PubMed ID: 34122068
    [No Abstract]   [Full Text] [Related]  

  • 30. A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects.
    Liu Z; Gao Z; Yang W; Zhang L; Xiao N; Qu D; Su Z; Xu K; Liu G; Wang Y; Ren Q; Yu S; Cheng Y; Zhou Y; Deng Q; Zhao Y; Wang Z; Yang H
    Expert Opin Drug Metab Toxicol; 2022; 18(7-8):519-527. PubMed ID: 35961948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects.
    Wang W; Zhang S; Dou C; Hu B; Song H; Qi F; Zhao Y; Li X; Zhou M; Xie J; Deng K; Wu Q; Ye L; Cui C; Liu L; Huang J; Yang G
    BioDrugs; 2024 Nov; 38(6):855-865. PubMed ID: 39317850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Randomized Pharmacokinetic Study in Healthy Male Subjects Comparing a High-concentration, Citrate-free SB5 Formulation (40 mg/0.4 ml) and Prior SB5 (Adalimumab Biosimilar).
    Ahn SS; Lee M; Baek Y; Lee S
    Rheumatol Ther; 2022 Aug; 9(4):1157-1169. PubMed ID: 35776269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta
    Sun Y; Yang H; Yang X; Yang S; Guo C; Chen H; Cui C; Xiang Y; Yang G; Huang J
    Front Pharmacol; 2022; 13():953641. PubMed ID: 36081953
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects.
    Wang S; Yang X; Huang J; Yang S; Wu Q; Chen H; Wu S; Dou C; Yang G; Xiang Y
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1133-1142. PubMed ID: 36045484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial.
    Dong W; Chen M; Niu S; Wang B; Xia L; Wang J; Shen T; Wang Q; Lv J; Liu G; Fan H; Xie Z; Xie F; An Y; Zheng Q; Rao H; Song H; Fang Y
    Expert Opin Biol Ther; 2022 Feb; 22(2):253-262. PubMed ID: 34236011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study.
    Lin Y; Yang H; Yang X; Guo C; Yang S; Yang G; Wu Q; Pan C; Sun C; Li C; He L; Huang J; Pei Q
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1125-1132. PubMed ID: 36112084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers.
    Cui Y; Cui D; Ren X; Chen X; Liu G; Liu Z; Wang Y; Qu X; Zhao Y; Yang H
    Front Pharmacol; 2021; 12():660541. PubMed ID: 34149414
    [No Abstract]   [Full Text] [Related]  

  • 38. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
    Knight B; Rassam D; Liao S; Ewesuedo R
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):839-46. PubMed ID: 26984210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects.
    Zhang H; Wu M; Zhu X; Li C; Li X; Sun J; Liu C; Liu Q; Wei W; Niu J; Ding Y
    Front Pharmacol; 2020; 11():01329. PubMed ID: 33132906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects.
    Sabet A; Dickerson DS; Kunina EE; Buccarello AL; Monnet J
    Rheumatol Ther; 2022 Apr; 9(2):693-704. PubMed ID: 35262901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.